AVE Science & Technology Co

AVE Science & Technology Co Equity Growth

The Year-over-Year Equity Growth of AVE Science & Technology Co (688067.SS) as of Nov 16, 2026 is 3.73 %. In the previous year, Year-over-Year Equity Growth was 1.22 % — a change of 204.77% (higher).

Equity Growth

3.73 %

YoY

204.77%

Last updated:

Year-over-Year Equity Growth of AVE Science & Technology Co is 2025 3.73 % . Year-over-Year Equity Growth of AVE Science & Technology Co was 2024 1.22 % . It decreases by 204.77% higher compared to the previous year.

The AVE Science & Technology Co Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
14.39 CNY
Jan 1, 2019
16.22 CNY
Jan 1, 2020
-6.25 CNY
Jan 1, 2021
101.75 CNY
Jan 1, 2022
-0.52 CNY
Jan 1, 2023
3.10 CNY
Jan 1, 2024
1.22 CNY
Jan 1, 2025
3.73 CNY
The AVE Science & Technology Co Equity Growth history
YEAREquity GrowthYoY
3.73 %+204.77%
1.22 %-60.48%
3.10 %-701.68%
-0.52 %-100.51%
101.75 %-1,727.19%
-6.25 %-138.56%
16.22 %+12.72%
14.39 %+111.30%
6.81 %-66.85%
20.54 %+207.02%
6.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

Year-over-Year Equity Growth of AVE Science & Technology Co is 3.73 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's AVE Science & Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co